Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | MTOR | P42345 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.49 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.49 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.49 |
| ▸ | GMNN | O75496 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.49 |
| ▸ | THPO | P40225 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fiacitabine SCHEMBL6715038 | 1.00 | PDE2A (0.50) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| Fiacitabine SCHEMBL6725815 | 1.00 | PDE2A (0.50) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| Fiacitabine SCHEMBL138935 | 1.00 | PDE2A (0.50) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| Fiacitabine SCHEMBL773659 | 1.00 | PDE2A (0.50) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| Fiacitabine SCHEMBL3120689 | 1.00 | PDE2A (0.50) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| Fiacitabine SCHEMBL15630217 | 1.00 | PDE2A (0.50) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| Fiacitabine SCHEMBL16943181 | 1.00 | PDE2A (0.50) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| Fiacitabine SCHEMBL1984820 | 1.00 | PDE2A (0.50) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| Fiacitabine SCHEMBL768016 | 1.00 | PDE2A (0.50) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| Fiacitabine SCHEMBL7464079 | 1.00 | PDE2A (0.50) | PDE2AADORA3ADORA2AADORA1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1999 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | claimed |
| WO-2026043843-A1 | TETRAHYDROPYRIMIDINE (THP) IONIZABLE LIPIDS FOR EFFICIENT MRNA DELIVERY | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, (US) | 2026-02-26 | — | — | WO | claimed |
| WO-2025076059-A1 | ROCAGLATE DERIVATIVES AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2025-04-10 | — | — | WO | claimed |
| WO-2024215771-A1 | SUBSTITUTED PHENYL ETHYNYL PYRIMIDINES AS POTENT INHIBITORS OF ALPHAVIRUSES | SOUTHERN RESEARCH INSTITUTE (US) | 2024-10-17 | — | — | WO | claimed |
| CN-115834293-B | Building private network construction method and building private network | 中国联合网络通信集团有限公司 | 2024-07-19 | — | — | CN | claimed |
| US-20240139325-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2024-05-02 | — | — | US | claimed |
| CN-117915401-A | Task unloading and resource allocation method for edge computing system in WiFi-cellular heterogeneous network | 北京邮电大学 | 2024-04-19 | — | — | CN | claimed |
| EP-4262812-A1 | 6-AZA-NUCLEOSIDE PRODRUGS AS ANTIVIRAL AGENTS FOR TREATING VIRUS INFECTIONS | Southern Research Institute (US) | 2023-10-25 | — | — | EP | claimed |
| CN-116450572-A | Power supply chain data storage optimization method and system based on block chain | 国网辽宁省电力有限公司信息通信分公司 | 2023-07-18 | — | — | CN | claimed |
| WO-2023122212-A2 | SUBSTITUTED PHENYL ETHYNYL PYRIDINE CARBOXAMIDES AS POTENT INHIBITORS OF SARS VIRUS | SOUTHERN RESEARCH INSTITUTE (US) | 2023-06-29 | — | — | WO | claimed |
| EP-0618226-A1 | Inhibitors of herpes viral ribonculeotide reductase | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1994-10-05 | — | — | EP | claimed |
| WO-1994020528-A1 | INHIBITORS OF HERPES VIRAL RIBONUCLEOTIDE REDUCTASE | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1994-09-15 | — | — | WO | claimed |
| WO-1993018056-A1 | ISOSTERIC ANTIHERPES PEPTIDE DERIVATIVES | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1993-09-16 | — | — | WO | claimed |
| EP-0560274-A1 | Antiherpes peptide derivatives having a ureido N-terminus | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1993-09-15 | — | — | EP | claimed |
| EP-0560267-A1 | Isosteric antiherpes peptide derivatives | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1993-09-15 | — | — | EP | claimed |
| EP-0493770-A2 | Antiherpes compositions | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1992-07-08 | — | — | EP | claimed |
| EP-0493767-A2 | Synergistic combination for treating herpes infections | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1992-07-08 | — | — | EP | claimed |
| EP-0010205-B1 | 5-SUBSTITUTED 1-(2'-DEOXY-2'-SUBSTITUTED-BETA-D-ARABINOFURANOSYL) PYRIMIDINE NUCLEOSIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Sloan-Kettering Institute For Cancer Research (US) | 1983-05-04 | — | — | EP | claimed |
| US-4211773-A | VIRICIDES, ANTITUMOR AGENTS | SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1980-07-08 | — | — | US | claimed |
| EP-0010205-A1 | 5-Substituted 1-(2'-deoxy-2'-substituted-beta-D-arabinofuranosyl) pyrimidine nucleosides and pharmaceutical compositions containing them | Sloan-Kettering Institute For Cancer Research (US) | 1980-04-30 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | HAVCR2, NR1H4, NR1H3 | PDE2A 4801/4885ADORA3 558/4885ADORA2A 1902/4885 |
| US-20240139325-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | SLC10A1, HAVCR2, HDGF | PDE2A 4804/4885ADORA3 3777/4885ADORA2A 4586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.